Uveitis is one of the most popular blind-causing eye diseases worldwide. Adalimumab (ADA) is used for the uveitis treatment through systemic or intravitreal injection at the expense of systemic side effects and increased medical risks. Although eye drops, a non-invasive topical treatment, could be a potential strategy to reduce side effects, it remains challenging to apply due to limited bioavailability mainly linked to poor retention time and permeation capacity for eye biological barriers. Here, we reported hydrogel eye drops composed of low-deacetylated chitosan and β-glycerophosphate as an ADA carrier and tested its toxicity, tolerability, intraocular permeability, and efficacy of non-invasive treatment for uveitis. It’s found the ADA-loaded hydrogel eye drops were more efficient than free ADA both in permeation rate and clinical efficacy for uveitis, Overall, this study provides a friendly non-invasive strategy to improve drug permeation rate and uveitis treatment efficacy, which may be valuable to clinically ophthalmic medication.

葡萄膜炎是全球最流行的致盲性眼病之一。阿达木单抗（ADA）通过全身或玻璃体内注射用于葡萄膜炎治疗，但以全身副作用和增加的医疗风险为代价。尽管滴眼剂（一种非侵入性的局部治疗）可能是减轻副作用的潜在策略，但由于生物利用度有限（主要与滞留时间和对眼生物屏障的渗透能力差有关），应用滴眼液仍然具有挑战性。在这里，我们报道了由低脱乙酰化壳聚糖和β-甘油磷酸作为ADA载体组成的水凝胶滴眼液，并测试了其毒性，耐受性，眼内通透性以及非侵入性治疗葡萄膜炎的功效。